S_ary We examined the microvascular effects of competitive nitric oxide synthase (NOS) inhibition with NM-monomethyl-L-arginine (MeArg), followed by L-argliine, on R3230Ac mammary adenocarcinoma perfusion. In (Chaplin and Acker, 1987; Brown and Koong, 1991) . It has been suggested that systemic administration of a hypoxic cell cytotoxin, followed by a drug that selectively reduces tumour blood flow, would augment cytotoxicity of such agents by trapping the cytotoxic agent within the tumour mass and increase their cytotoxicity via induction of hypoxia (Chaplin, 1989) ; this approach has recently been validated using NoArg and RB6145 in a transplantable murine tumour system (Wood et al., 1994). Selective reduction of tumour blood flow could also lead to enhanc efficacy of hyperthermia because of reduced heat transfer, resulting in improved temperatures during heating and increased cytotoxicity of hypoxic, acidotic cells (Dewhirst et al., 1990) .
A relatively new and novel approach to solid tumour therapy has involved the induction of tumour hypoxia following the administration of drugs that are seectively cytotoxic to hypoxic cells (Chaplin and Acker, 1987; Brown and Koong, 1991) . It has been suggested that systemic administration of a hypoxic cell cytotoxin, followed by a drug that selectively reduces tumour blood flow, would augment cytotoxicity of such agents by trapping the cytotoxic agent within the tumour mass and increase their cytotoxicity via induction of hypoxia (Chaplin, 1989) ; this approach has recently been validated using NoArg and RB6145 in a transplantable murine tumour system (Wood et al., 1994) . Selective reduction of tumour blood flow could also lead to enhanc efficacy of hyperthermia because of reduced heat transfer, resulting in improved temperatures during heating and increased cytotoxicity of hypoxic, acidotic cells (Dewhirst et al., 1990) .
Solid tumours are a heterogeneous population of cell types, including tumour, vascular and infiltrating immune cells. GeneraDly speaking, tumour blood supply is derived from both existing normal tissue and from newly generated fibrovascular stromal reaction (Peterson, 1991) . Although rapidly growing transplantable rodent tumours do not possess very much vascular smooth muscle, with much of their blood supply derived from arteioles that enter the tumour from surrounding normal tissue parenchyma, this is probably not the case for many slow-growing human tumour xenografts, spontaneous rodent tumours and clinical human tumours. Thus, while the involvement of the surrounding normal vasculature in supplying tumour blood flow may be important, it may not be the only controlling factor.
The free radical gas nitric oxide (NO), which was previously identified as endothelium-derived relaxant factor (Ignarro et al., 1987; Palmer et al., 1987) , is generated by conversion of L-arginine to L-citrulline in the presence of nitric oxide synthase (NOS). The dence, but this classification does not uniformly hold for all isoforms. Constitutive, calcium-dependent, NO synthases are found in the vascular (eNOS) and neuronal systems (bNOS) and produce NO as part of a signal transduction mechanism. In contrast, NOS induced by cytokines and endotoxin (iNOS) provides for sustained release of NO as part of the immune-mediated response, however both calcium-dependent and -independent forms of iNOS have been described in tumours (Sherman et al., 1993; Thomsen et al., 1994) . MeArg, a competitive inhibitor of both the calcium-dependent and -independent forms of NOS, results in arteriolar vasoconstriction and hypertension . NOS inhibition has recently been shown to reduce global tumour and normal tissue perfusion, as indiectly determined by inert gas washout (Andrade et al., 1992) and inorganic phosphorus energy status (Wood et al., , 1994 . Wholeorgan measurements such as these, however, do not provide information on heterogeneity of regional microvascular perfusion. As oxygen exchange within tumours occurs primarily from venules (Secomb et al., 1993) , and the oxygen diffiusion distances from perfiused vessels within tumours are reported to be less than 100 gam (Dewhirst et al., 1994) , direct observation of venules can provide a means to describe regional changes in tumour microvascular perfusion that are relevant to oxygen transport.
The purpose of this study was to examine the regional microvascular effects of NOS inhibition, followed by Larginine, on tumour and surrounding tissue perfusion. Our null hypothesis was that treatment with MeArg, followed by L-arginine, would not to pretreatment levels ( Figure 1, all P <0.05) (Figure 2) . Central tumour venule RBC velocity.
however, was further reduced from baseline following Larginine (to 61% of baseline; P <0.05), and remained significantly lower than that of both peripheral tumour venules and normal venules near tumours (P = 0.05 and P = 0.03 respectively).
MeArg had no effect on length density in tumour preparation venules, although treatment tended towards reducing length density in tumour preparation venules ( (Hogan et al.. 1988 : Yao et al.. 1992 . increases leucocyte adhesion. extravasation and migration (Kubes et al.. 1991) and increases leucocyte-dependent and -independent microvascular permeability (Kubes and Granger. 1992 (Pollock et al.. 1991) . Optimisation of NOS inhibitor and L-arginine concentration and kinetics will be necessary in order to fully exploit this potential therapy.
We have observed that inhibition of NOS reduces both tumour and normal microvascular perfusion and that subsequent administration of L-argimne can restore normal tissue, but not tumour, perfusion. Tumours may influence their own microvascular perfusion as well as perfusion in surrounding tissues by inducing NOS production. Tumour NOS inhibition followed by normal tissue rescue with administration of L-argirmne may provide a novel means of achieving the therapeutic goal of selective tumour hypoxia.
Abbreviatioas NO, nitric oxide; NOS. nitric oxide synthase; eNOS. endothelial NOS; bNOS. neuronal or brain NOS; iNOS. inducible NOS: MeArg. VG-monomethyl-L-arginine: NoArg. N-nitro-Larginine: EBSS. Earle's balanced salt solution; IL. interleukin; TNF. tumour necrosis factor.
